Safety, Efficacy and Pharmacokinetics of an Antibody for Psoriatic Arthritis
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a humanized monoclonal antibody
(efalizumab) is safe and effective in the treatment of psoriatic arthritis (PsA)